We assessed the prognostic value of PDE10A protein expression in 149 patients with stage I–II NSCLC (Table S2), followed during a median period of 46.5 months (interquartile range: 91.6–22.0). This evidence concerns the gene PDE10A and non-small cell lung carcinoma.